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Purpose: Photoacoustic (PA) imaging is a recently developed breast cancer imaging technique. 
In order to enhance successful clinical implementation, we quantified the potential clinical value 
of different scenarios incorporating PA imaging by means of multi-criteria analysis. From this 
analysis, the most promising area of application for PA imaging in breast cancer diagnosis is 
determined, and recommendations are provided to optimize the design of PA imaging.
Methods: The added value of PA imaging was assessed in two areas of application in the 
diagnostic track. These areas include PA imaging as an alternative to x-ray mammography 
and ultrasonography in early stage diagnosis, and PA imaging as an alternative to Magnetic 
Resonance Imaging (MRI) in later stage diagnosis. The added value of PA imaging was assessed 
with respect to four main criteria (costs, diagnostic performance, patient comfort and risks). 
An expert panel composed of medical, technical and management experts was asked to assess 
the relative importance of the criteria in comparing the alternative diagnostic devices. The 
 judgments of the experts were quantified based on the validated pairwise comparison technique 
of the Analytic Hierarchy Process, a technique for multi-criteria analysis. Sensitivity analysis 
was applied to account for the uncertainty of the outcomes.
Results: Among the considered alternatives, PA imaging is the preferred technique due to its 
non-invasiveness, low cost and low risks. However, the experts do not expect large differences 
in diagnostic performance. The outcomes suggest that design changes to improve the diagnostic 
performance of PA imaging should focus on the quality of the reconstruction algorithm, detector 
sensitivity, detector bandwidth and the number of wavelengths used.
Conclusion: The AHP method was useful in recommending the most promising area of 
application in the diagnostic track for which PA imaging can be implemented, this being early 
diagnosis, as a substitute for the combined use of x-ray mammography and ultrasonography.
Keywords: technology assessment, breast cancer, diagnostic imaging, biomedical engineering
Introduction
At the current rates of incidence, about 1 in 8 women in the Netherlands will develop 
breast cancer, and 1 in 22 women will die of the disease.1 Incidence risk increases in 
the middle years of a woman’s life rather than the advanced years as with other types of 
cancer. Thus, the number of years lost by those succumbing to breast cancer is higher 
than with other cancers. The current paradigm of breast cancer mortality reduction is 
based on early detection followed by effective intervention.
The diagnosis of breast cancer in Europe is based on triple assessment: clinical 
examination; imaging; and cytological/histological sampling, often in a single visit. 
The accuracy of triple assessment depends on the quality of each constituent test.2,3 
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The most frequently used imaging techniques within the triple 
assessment are x-ray mammography and ultrasonography, 
either alone or in combination. Magnetic resonance 
 imaging (MRI) is also becoming more established and 
widely used.3
There are several drawbacks regarding the use of these 
imaging techniques. X-ray mammography offers poor 
contrast in radiodense glandular breasts, and the use of 
ionizing radiation offers some concern due to its associated 
carcinogenic potential. Furthermore, patients complain about 
the discomfort in x-ray mammography. Ultrasonography 
plays an adjunctive role to x-ray imaging in solid mass-cyst 
differentiation. However, there is not yet any large-scale 
application of the technique to differentiate malignant from 
benign abnormalities, and the results are strongly operator 
dependent. MRI is gaining a niche role as a problem solving 
technique in certain cases such as with uncertain findings in 
mammography and ultrasonography. However, it requires 
the use of contrast agent, and has shown poor specificity. 
Moreover, MRI is more expensive than the other imaging 
techniques, and therefore has limited accessibility.4 
In conclusion, all these techniques have several drawbacks 
felt both at individual and societal levels: distress, pain, false 
reassurance, morbidity and mortality, as well as direct and 
indirect financial burden.
A new technology, photoacoustic (PA) imaging, 
has recently gained much attention in imaging various 
pathological states related to vascular condition and function.5 
Some important applications of this technique include breast 
cancer visualization.6,7 This technique has the potential to 
address at least some of the drawbacks of the conventional 
techniques. The technique relies on irradiating tissue with 
nanosecond pulses of visible or near infrared (NIR) light. 
Optical absorption in tissue causes thermoelastic expansion, 
which produces broadband pulses (MHz) of ultrasound 
energy. These pulses propagate through the tissue and can 
be detected at the tissue surface at multiple positions using 
ultrasound detectors.7 Tumor growth is associated with 
enhanced blood vessel supply generated in the process 
called angiogenesis. Blood in this enhanced vascularization 
absorbs light strongly and endows an absorption contrast to 
the cancer. Therefore, the PA imaging technique might be 
valuable for the large group of women potentially suffering 
from breast cancer. The proof of principle of PA imaging in 
breast cancer detection has been demonstrated in restricted 
studies using near-infrared (NIR) light in an instrument 
developed at the University of Twente (the Netherlands), 
called the Twente Photoacoustic Mammoscope PAM.7,8
As the choice for any imaging technique involves multiple 
decision criteria, a formal assessment of the added value of a 
new diagnostic device should take a prioritized set of criteria 
into account. For the implementation of PA imaging, different 
areas of application in the diagnostic track for breast cancer 
can be chosen, each with their own benefits and drawbacks, 
and relevant criteria. Early technology assessment can be 
applied to evaluate the possible success of PA imaging in 
each of these areas of application. Forward thinking about 
the future clinical application of a technology that is still 
in development is also part of Constructive Technology 
Assessment (CTA) and Real-time Technology Assessment 
(RTA). Such early assessments of a technology that take 
into account expert judgment and discussion, early data on 
patients, and first experiences with a technology, can result 
in relevant recommendations. These recommendations can 
fine-tune the further development of the new technology, 
such as PA imaging, to the requirements of clinical practice. 
This has also been demonstrated in different studies using 
CTA or RTA for early assessment of nanotechnology and 
oncology applications.9–17 Early technology assessment can be 
conducted by using multi-criteria decision analysis (MCDA) 
methods. Multi-criteria decision analysis can support the 
evaluation of a technology with respect to different outcome 
measures. It helps decision-makers to evaluate a finite number 
of alternatives under a finite number of performance criteria. 
Saaty’s mathematical model, the analytic hierarchy process 
(AHP), is one of these techniques for multi-criteria decision 
analysis.18 It was initially introduced to support strategic 
decisions in industry, but the technique is also applicable 
in different stages of health technology development and 
diffusion.19
In this study, we applied AHP analysis to an initial 
comparison of the expected performance of PA imaging with 
conventional diagnostic mammography techniques. This 
systematic, transparent method of assessment by a small, 
multidisciplinary group of experts will provide the developers 
of PA imaging with useful feedback about possible 
improvements to their technique, and can aid decisions they 
still need to make. We used the outcomes of the analysis to 
determine the most promising area of application for PA 
imaging in breast cancer diagnosis.
Methods
Defining areas of application  
in the diagnostic track for breast cancer
Diagnosis of breast cancer mainly starts with clinical 
examination, followed by basic imaging procedures, such as 
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mammography and ultrasonography, prior to any clinically 
guided tissue sampling. The use of these basic imaging 
procedures will be referred to as “early diagnosis” in this 
study. Mostly, early diagnosis starts with mammography. 
Ultrasound imaging is used if the tumor is mammographically 
occult, but also if visible on the x-ray as part of the standard 
triple assessment procedures.2,3 Further ultrasonography is 
the initial diagnostic imaging method applied for women 
under the age of 35 years, where the use of x-rays is not 
recommended.2,3
MRI is increasingly used in later stages of breast cancer 
diagnosis. MRI is of proven value in helping to establish 
the degree of disease present where malignancy is already 
established or highly likely in dense breasts, or with tumors 
having a likelihood of multifocality, multicentricity or 
 bilaterality. MRI has also been shown to have a high sensitivity 
in the detection of malignancy in younger women at high risk, 
and MRI is currently recognized as the method of choice for 
investigating significant abnormalities in the breast in the 
presence of implants. The use of MRI in breast cancer diagnosis 
will be referred to as “late diagnosis” in this study.3
Both early and late diagnosis are expected to be suitable 
areas of application for PA imaging in breast cancer 
diagnosis.
AHP analysis
The first step in the AHP analysis is to define the framework, 
or hierarchical structure, for the analysis. This framework 
consists of the goal, criteria and the alternative imaging 
techniques.
goal
The goal of this AHP analysis is to compare the expected 
performance of PA imaging with the conventional techniques 
used in different areas of application in the diagnostic track 
for breast cancer.
criteria
To identify relevant criteria for AHP analysis, a literature 
search was performed, followed by several discussions at the 
Centre for Mammacare in a large Dutch teaching hospital. 
On the basis of the literature study and discussions with 
engineers and radiologists, relevant factors were identified 
that determine the quality of a breast imaging device. These 
factors were used to compose the hierarchical evaluation 
structure (see Figure 1).
The top-level criteria in the hierarchical structure: costs; 
effectiveness; patient comfort; and risks, are from the 
European guidelines for breast cancer diagnosis.3 The costs 
subcriteria followed from an interview with the finance 
department of the Dutch teaching  hospital. The effectiveness 
subcriteria were identified from  clinical breast imaging 
guidelines and literature, and from the world-wide classi-
fication standard for breast lesions, BI-RADS.4,20 The most 
frequently mentioned tumor aspects in these documents are 
presented in the hierarchy. Oxygen saturation was added 
to the effectiveness  subcriteria, because the presentation of 
information about oxygen saturation of the blood associated 
with the tumor is a unique feature that PA imaging potentially 
offers, and the AHP results may show if this new feature 
will be important. Patient comfort subcriteria were derived 
1.1 Scan time
2.1 Sensitivity 2.2 Specificity
3.1 Body contact
3.2 Environmental factors
3.3 Time between scan and results
4.1 Physical exposure
4.2 Chemical exposure
4.3 Bodily burden2.1.1 Mass margins
2.1.2 Mass shape
2.1.3 Mass size
2.1.4 Location mass
2.1.6 Vascularization
2.1.7 Oxygen saturation
2.1.5 Ca++
2.2.1 Mass margins
2.2.2 Mass shape
2.2.3 Mass size
2.2.4 Location mass
2.2.6 Vascularization
2.2.7 Oxygen saturation
2.2.5 Ca++
1.2 Manpower
1.3 Price
(maintainance/disposables)
1.4 Peripheral equipment
(ICT and environment)
1 Costs 3 Patient comfort
4 Safety/risks2 Effectiveness
Compare diagnostic breast imaging modalities
Figure 1 AHP hierarchical structure.
Abbreviation: AHP, analytic hierarchy process.
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from patient information from different cancer institutes, 
societies, and patient organizations.21 The risks subcriteria 
were determined from incident analyses and an interview 
with a medical physicist.
Alternatives
PA imaging was compared to conventional mammography 
techniques used in both early and late diagnosis.
Only a limited amount of data and clinical prototypes are 
available for PA breast imaging.7,8 We thus used the technical 
specifications and performance (past and predicted) of the 
Twente Photoacoustic Mammoscope, PAM II, as being 
representative for PA imaging in general. Comparisons are 
made with the current technologies that PA imaging aims 
to substitute or will compete with: x-ray mammography, 
ultrasonography and MRI.
PAM II is a prototype PA imaging device being 
developed by the Biomedical Photonic Imaging group of 
the University of Twente. An overview of the expected 
specifications of PAM II is provided in Table 1. PAM II 
will produce tomographic images of the full breast. During 
scanning, the patient lies in a prone position with her 
breast hanging in an imaging tank filled with water at body 
temperature. The laser and detector matrix spin around in 
this tank and multiple projections of the breast are acquired. 
The use of a dedicated reconstruction algorithm and 
multiple wavelengths of light in this prototype will offer the 
possibility of the production of images of vascularization 
associated with breast carcinoma, and information about 
the level of oxygen saturation of the blood in the tumor 
vessels.
Table 1 Overview of expected specifications PAM II
Item Value
scan time 15–20 minutes per breast
Expected price of purchase €400.000
in plane resolution ,1 mm
Depth resolution ,1 mm
Max. imaging depth 50+ mm
Reconstruction 3D
scan area Full-breast (40 mm radius)
Patient position Prone position
Breast compression none
Radiation hazard non-ionizing radiation 
Laser safety measures needed
Availability of results Within 2–3 days, after evaluation 
by trained radiologist
contrast medium Blood 
no contrast agent needed
Functional tumor aspects visible Blood vessels 
Oxygen saturation (%)
Table 2 composition of AHP expert team
No. Profession Core PAM activity/relation
1 Manager* costs for health care organization
2 Medical specialist  
(Radiologist)*
User
3 nurse practitioner/ 
radiology assistant*
User, patient representative
4 Physicist Technical design of PAM
5 Laser physicist Technical design of PAM,  
optical engineering
6 Physicist Research in one of the world’s  
leading medical device companies,  
main interest in optical mammography
7 Medical physicist safety and Quality assurance
Note: *These professions were represented by different persons during the first 
and the second session.
Abbreviations: PAM, Twente Photoacoustic Mammoscope; AHP, analytic hierarchy 
process.
It is assumed that PA imaging will replace one or 
more conventional techniques, instead of being used as an 
additional technique in the diagnostic track. This assumption 
is made because additional methods usually result in an 
extended diagnostic pathway at higher cost and therefore 
prevent implementation. This means that, for early diagnosis, 
the alternatives used in the AHP analysis are: the combined 
use of x-ray mammography and ultrasonography; the 
combined use of x-ray mammography and PAM II (PAM II as 
a substitute solely for ultrasonography); and the use solely of 
PAM II (PAM II as a substitute for both x-ray mammography 
and ultrasonography). For late diagnosis, the alternatives 
used in the AHP analysis are: MRI and PAM II. Both sets of 
alternatives, each corresponding to one area of application, 
were evaluated separately, because they are implemented 
for other patient groups, and other performance data may 
be important.
Expert panels
Two expert teams were invited to participate in the AHP 
 analysis, with the inclusion of appropriate professional 
experts in case of early diagnosis and late diagnosis. 
In  interviews with the developers of PAM II and with 
different medical experts, a multidisciplinary panel of experts 
was identified. Table 2 presents the invited team members 
together with their professional backgrounds.
AHP session
All members of the AHP expert team had received informa-
tion about the AHP hierarchy and a performance matrix, 
containing relevant facts about all alternatives, in advance. 
A day-section feedback session was organized in which the 
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expert team discussed the relative importance of the criteria, 
subcriteria, and the pursued quality of each diagnostic 
alternative. This was supported using Team Expert Choice 
software (Expert Choice, Arlington, VA), a commercially 
available group decision support system that incorporates 
the mathematical procedures of the AHP.22 The feedback 
session started with an introduction of the software and the 
procedures of Team Expert Choice and the developer of 
PAM II explained the principles of this diagnostic device. 
The AHP hierarchy was also explained. Then, using hand-
held remote controlled keypads, the members of the expert 
team provided their judgments on pairwise comparisons of 
the importance of the selected subcriteria, and preference 
for the selected alternatives. Individual judgments were 
projected on a screen, allowing the members of the expert 
team to discuss the rationales behind their individual scores. 
During the discussions, the expert team members had the 
opportunity to alter their judgments. To support the team 
members and to make sure every expert used the same defi-
nition of a subcriterion, the descriptions of the subcriteria 
that were assessed were displayed on a second screen. For 
each pairwise comparison, the final individual judgments 
were aggregated, based on the geometric mean, to create 
group weighting factors representing the importance of the 
subcriteria and the priorities reflecting the relative preference 
for the alternatives.
sensitivity analysis
Because PA imaging, and especially PAM II, is early in its 
development and only a limited amount of data has been 
obtained to date, its performance is uncertain. It is expected 
that this uncertainty mainly exists regarding the sensitivity 
and specificity of PAM II. The experts individually assessed 
this uncertainty about the different pairwise judgments 
regarding sensitivity and specificity, using a 3-point scale. 
Based on the uncertainty expressed, three scenarios were 
constructed: negative, average and positive, for PAM II. These 
scenarios were used in a sensitivity analysis regarding the 
predicted performance of PA imaging.
Results
The results of the AHP analysis are presented in Figure 2, 
which shows the results of the comparison of PAM II with 
x-ray mammography and ultrasonography (early diagnosis), 
and in Figure 3, which shows the results of the comparison 
of PAM II with MRI (late diagnosis).
0,12
Peripheral
equipment
(1%)
Sensitivity
(48%)
Specificity
(7%)
Body contact
(3%)
Environmental
factors
(1%)
Time
between
scan and
results
(5%)
Physical
exposure
(4%)
Chemical
exposure
(10%)
Bodily
burden
(13%)
0,10
0,08
0,06
0,04
0,02
−0,02
−0,04
−0,06
−0,08
−0,10
−0,12
0,00
Scan time
(4%)
Manpower
(3%)
Price
(2%)
0,5
0,45
0,4
0,35
0,3
0,25
0,2
0,15
0,1
0,05
0
Neg. Av. Pos.
Mammography and US
Mammography and PAM II
PAM II
O
ve
ra
ll 
p
ri
o
ri
ty
A
B
W
e
ig
h
te
d
 i
m
p
a
c
t 
o
n
 p
re
fe
re
n
c
e
s
Figure 2 Results of early diagnosis. (A) importance of the criteria, and relative preference for the breast imaging alternatives with respect to the criteria, early diagnosis. 
(B) Overall preferences for the alternatives, early diagnosis.
Abbreviations: neg, negative scenario; av, average scenario; pos, positive scenario.
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At the top of Figures 2A and 3A, the relative importance 
of the criteria, resulting from the pairwise comparisons in the 
AHP, is expressed in percentages, between brackets. The lines 
below each criterion reflect the relative preference for each 
breast imaging alternative with respect to that criterion, multi-
plied by the relative importance of that criterion. Thus, a larger 
deviation from 0 reflects a more discriminating  criterion. For 
example, in the comparison of mammography, ultrasonography 
and PAM II (Figure 2A), the preference for PAM II with respect 
to bodily burden is an important contributor to the overall 
preference for one of the breast imaging alternatives.
The most important aspect of a diagnostic breast imag-
ing device is its diagnostic performance, especially with 
respect to sensitivity (48%–49%, see Figures 2A–3A). This 
means that a change in the design of a breast imaging device 
which affects the sensitivity is expected to have the largest 
impact on the relative preference for that device. However, 
the  performance of the different breast imaging alternatives 
with respect to sensitivity is not expected to be very different, 
so “sensitivity” is in this case not the most discriminating 
factor for the overall preference.
The main factors that determine sensitivity in an image are 
the representation of mass margins (relative weight = 0.119), 
mass shape (0.106), vascularization (0.106) and oxygen 
saturation (0.123). The relative weights for these factors 
result from the AHP analysis of the subcriteria.
The bars around the average sensitivity and specificity 
scores in Figures 2A and 3A show the results of the sensitivity 
analysis applied to the diagnostic performance of PAM II. 
In Figures 2B and 3B, the height of the bars reflects the 
relative preference for each of the alternatives. Three different 
scenarios resulting from the sensitivity analysis are shown. 
Figures 2B and 3B show that with increasing positivity, PAM 
II becomes a more preferred option. Compared to x-ray 
mammography and ultrasonography, PAM II is, even in the 
most negative scenario, the most preferred option. This is 
not true for the performance of PAM II compared to MRI, 
which shows a slight preference for MRI in the most negative 
scenario in the sensitivity analysis.
From the figures, it becomes clear that PA imaging is a 
preferred technique due to its non-invasiveness, low cost and 
low risk. The experts do however not expect a large difference 
in the overall diagnostic performance of PA imaging, either 
with mammography and ultrasonography or with MRI.
Sensitivity was rated as the most important aspect of a 
diagnostic breast imaging device. The representation of mass 
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Figure 3 Results of late diagnosis. (A) importance of the criteria, and relative preference for the breast imaging alternatives with respect to the criteria, late diagnosis. 
(B) Overall preferences for the alternatives, late diagnosis.
Abbreviations: neg, negative scenario; av, average scenario; pos, positive scenario.
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margins, mass shape, vascularization and oxygen saturation 
in an image are factors that mainly determine the expected 
performance with respect to sensitivity. Therefore, in order 
to improve the diagnostic performance of PAM II, technical 
improvements should be carried out that are focused on 
improvement of these factors. These technical improvements 
will include adjustments to the reconstruction algorithm, the 
sensitivity of the detector, the bandwidth of the detector, and 
the number of wavelengths of light used.
Discussion and conclusion
The goal of this study was to compare PA imaging with 
conventional diagnostic mammography techniques, in order 
to determine the most promising area of application for 
PA imaging in breast cancer diagnosis. The overall results 
indicated that, based on the expected performance in terms 
of cost, effectiveness, patient comfort and risk criteria 
assessed, PAM II will be a preferred alternative. At the 
current stage, the experts’ judgments do not result in strong 
differences in the overall value of the alternative diagnostic 
devices. The sensitivity analysis showed that only in the 
most negative  scenario, will MRI be a preferred alternative 
to PAM II. All other scenarios result in PAM II being the 
most preferred option.
The most promising area of application for PA imaging 
is expected to be early diagnosis, as a substitute for the 
combined use of x-ray mammography and ultrasonography. 
This alternative was preferred even in the negative scenario 
in the sensitivity analysis (Figures 2B–3B). In addition, 
the preference for PAM II with respect to the risk and cost 
factors was larger when PAM II was compared to x-ray 
mammography and ultrasonography, than when PAM II was 
compared to MRI.
The results showed that PAM II was preferred over 
the other alternatives with respect to physical exposure 
(Figure 2A–3A), chemical exposure (Figure 3A) and bodily 
burden (Figure 2A–3A). Because PAM II does not make use 
of potentially harmful ionizing radiation, physical exposure 
is less than for both the mammography options. Furthermore, 
in the conventionally used x-ray mammography devices, the 
breast is forced between two plates, which can be a painful 
experience. Because in PAM II the breast is situated in an 
imaging tank without any compression, PAM II is a strongly 
preferred option regarding bodily burden. Compared to 
MRI, the non-invasiveness of the PAM II procedure was 
preferred over the invasive procedure of MRI, which requires 
the injection of contrast agent. This contrast agent is also 
expected to carry a small risk regarding chemical exposure. 
Furthermore, costs are expected to be lower for PAM II, 
mainly because only the use of a single device is needed 
opposite to the use of more devices, or the use of an expensive 
MRI system, in the other alternatives.
In both early and late diagnosis, sensitivity is by far 
the most important aspect. From the AHP analysis of the 
 sensitivity subcriteria, it followed that the representation of 
mass margins, mass shape, vascularization, and oxygen satu-
ration in an image are most needed for accurate sensitivity. 
Investing in the development of a good reconstruction 
algorithm, a high sensitivity detector, a large detector 
bandwidth, and a multi-wavelength light source for PAM II, 
will improve its performance with respect to these criteria.
The AHP proved to be suitable for early  technology 
assessment of PA imaging. Important design criteria 
were identified, and a substantiated prognosis of the most 
promising area of positioning PA imaging was given. When 
applying these methods, the following methodological 
considerations should be kept in mind.
In our problem definition we made the assumption that 
PA imaging will be a substitute, therefore we only identified 
conventional imaging techniques as being alternatives for 
PA imaging. Looking to the future, there might be other 
alternatives for PA imaging, such as positron emission 
tomography – computed tomography (PET-CT) and magnetic 
resonance elastography (MR-elastography) applications that 
have not been taken into account in the analysis. These new 
techniques might be used in addition to the conventional 
techniques, but their performance and future implementation 
in health care is unsure. In order to reduce complexity, we 
only considered imaging techniques applied in clinical 
practice. However, one needs to keep in mind that other 
relevant alternatives can arise over time.
The medical, social, industrial and technical backgrounds 
of the panel members influence their judgments about 
the importance of the decision criteria and the value of 
the diagnostic devices. Therefore it is essential that a 
representative group of experts are asked to participate in 
an expert panel. In this case, the categories of experts were 
chosen to match the types of criteria that were assessed. The 
patient comfort expert was chosen to be a nurse practitioner, 
as being best able to judge or predict patient response, in 
the absence of known patients who had experience with PA 
imaging. The experts were identified based on interviews 
with the developers of PAM II and with different medical 
experts. All experts are well-known at national level, for their 
research and experience with mammographic techniques. We 
were aware of the fact that the subjectivity of a small group 
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could influence the outcomes. However, because insiders 
with relevant knowledge were represented in our expert 
team, we obtained relevant outcomes for this early phase of 
development of PA imaging. In later developmental phases, 
closer to implementation, it becomes more important to 
include larger groups of experts, including patients.
Ideally, the experts would have been equally distributed 
over the different fields, but, in our analysis, the number of 
engineers was rather large compared to the other experts. 
To check if the engineers assessed the criteria differently 
from the other experts, a subgroup analysis was carried 
out. Results of this subgroup analysis showed that for the 
 engineers, costs and effectiveness were more important than 
for the other experts. The other experts judged patient  comfort 
and safety as more important aspects than the engineers. 
However, the relative order of importance of the criteria was 
similar for both groups. PAM II is slightly less preferred by 
the engineers than by the other experts, because of the lower 
expected effectiveness. The experts who were involved in the 
creation of PAM II did not show deviating judgments from 
the other engineers.
It was also important that the team had an equal basic 
knowledge about the new technology, so that discussions 
focus efficiently on knowledge-sharing between the experts 
to gain new insights for further development of PAM II. We 
sent panel members state-of-the-art literature before the 
session, and staged presentations by the relevant stakeholders 
before the panel discussions. During the panel session itself 
we allowed sufficient time for sharing knowledge about the 
relevant values of the diagnostic devices.
The criteria used in this analysis were identified mainly on 
the basis of literature and interviews with different experts. 
We were aware that this set of criteria might not provide a 
complete view of the situation; the AHP structure becomes 
too extensive if all relevant criteria have to be taken into 
account. We chose to define the set of criteria before the 
AHP session took place. Hummel et al indicated that it is 
also possible to let the definition of the criteria be part of the 
AHP session.9 This may create more consensus about the 
most important criteria.
In addition, a consensus still needs to be reached about 
the number of decision criteria to include in the assessment. 
More decision criteria increases the amount of detailed 
information discussed, but increases the cognitive load 
due to the increased number of pairwise comparisons. The 
cognitive load of our extensive AHP structure appeared 
to cause some cognitive fatigue. It is therefore important 
to keep the hierarchy as simple as possible, and to have a 
well-informed discussion leader for the AHP, who can keep 
the expert team focused on the exact content of the issues 
being addressed.
The interdependence of decision criteria that are used 
for the AHP analysis should be minimized. Considering 
the overlap that appeared between some of the subcriteria 
of costs, we advise using “costs” only as a main criterion 
in the AHP analysis, and using conventional accountancy 
methods to calculate the overall costs created by different 
sub-components.
Taking into account the above aspects, it can be con-
cluded that AHP is able to provide a useful prediction of 
the possible future success of a new technology. In this 
case the developers of PA imaging devices know now that 
their devices have a realistic chance of success, which is an 
important argument to encourage investment in the further 
development of the device. During the AHP analysis in this 
study, useful interdisciplinary discussions took place that 
provided the developers not only with new insights about 
the likely values and relevant improvements of PAM II, but 
also with an opportunity to inform, interact with, and pos-
sibly win over a group of potential users, which is expected 
to enhance acceptability. In addition it provided an overview 
of the main uncertainties in the outcomes. One example is 
the presentation of oxygen saturation. There are questions 
about the exact diagnostic value PAM II can offer with this 
information. More research is needed about the exact way 
in which this parameter can support diagnosis. The radiolo-
gists were curious about the visualization of this parameter 
in the image, it is therefore suggested that they judge several 
concepts, and develop the visualization in cooperation. The 
outcomes of this assessment indicate relevant directions for 
further research in diagnostic imaging.
The AHP method proved to be valuable in assessing 
the value of PA imaging in the diagnostic track for breast 
cancer. It showed that PA imaging can best be positioned 
at the start of the diagnostic track as an alternative to x-ray 
mammography and ultrasonography. Therefore, in the 
further development of PAM II, more specific issues and 
questions that arise in early diagnosis should be examined, in 
order to make PAM II optimally suitable for this diagnostic 
demand.
Our future research will focus on the use of the AHP 
method for early technology assessment to assess the value 
of PA imaging in screening. Application of PA imaging in 
screening might be beneficial for a lot more women. Current 
screening methods do not provide completely satisfactory 
results with respect to effectiveness, and the radiation risk 
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Assessment of photoacoustic imaging in breast cancer diagnosis
from conventional x-ray mammography is still an issue. 
Also, patient comfort is expected to be more important 
because a high quality screening program demands good 
cooperation from the patients. The performance of PA 
imaging with respect to other alternatives could also be 
investigated. Nuclear medicine is becoming more popular 
within cancer diagnosis, and new applications of MRI are 
being  developed, such as MR elastography, that may become 
serious competitors to PA imaging.
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